ADC shrinks brain metastases in HER2+ breast cancer patients
Phase II results show a high intracranial response rate in breast cancer patients with active brain metastases treated with trastzumab deruxtecan (T-Dxd), an antibody-drug conjugate (ADC).
List view / Grid view
Phase II results show a high intracranial response rate in breast cancer patients with active brain metastases treated with trastzumab deruxtecan (T-Dxd), an antibody-drug conjugate (ADC).
EPR discusses the findings of a recent study exploring whether microbicidal treatments using radiation cause the degradation of crude herbal medicinal components.
US and European Pharmacopoeias announce new activities to help promote vaccine development, manufacturing, quality and supply.
Cold chain shipping challenges & root causes of common reference product sourcing problems.
How shortening the timeline from development to clinic can be achieved through parallel processing versus using a task/time compression approach.
Collaboration between comparator sourcing specialists and clinical supply managers can improve inventory management and supply chain performance.
Learn the differences in areas of expertise and responsibilities between the Clinical Supply Manager, Project Manager and Financial Project Analyst.
The current understanding among sponsors of the workflow from cell collection, to manufacturing, and to the clinical site for patient administration.
Understand the perceived importance of DTP to successful study execution.
Single use technologies is highly booming in biopharmaceutical sector due to its efficient use and benefits.
Here, EPR discusses critical considerations to ensure content uniformity in HPAPI drugs produced using dry techniques.
A data collection study provides a product quality dataset that could form the basis of advanced analytical models to predict final product quality.
Research reveals how combining sample sectioning with Raman imaging enables the three-dimensional (3D) imaging of an oral solid dosage form matrix.
The importance of thoroughly planned resupply strategies in maintaining clinical supply inventories as studies move into late phase.
The demand for biologics and high potent medicines is forcing the industry to consider alternatives, such as outsourcing and integrated solutions.